Application of salvianolic acid A in preparation of medicine for resisting tunica intima thickening, post-angioplasty restenosis and/or in-stent restenosis

An angioplasty and vascular intima technology is applied in the application field of salvianolic acid A in the preparation of anti-intimal thickening, anti-angioplasty and/or in-stent restenosis drugs, and can solve the problem of unseen dandruff. Phenolic acid A application reports and other issues, to achieve significant vascular intimal thickening and lumen restenosis, reduce restenosis rate, anti-intimal thickening and lumen restenosis effect

Inactive Publication Date: 2016-03-30
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In recent years, studies have found that salvianolic acid components in Danshen have stronger anti-myocardial ischemia and hypoxia activity than danshensu and protocatechualdehyde, among which salvianolic acid A is one of the strongest antioxidant compounds currently known. , so far there is no report on the application of salvianolic acid A in the preparation of drugs for anti-intimal thickening and restenosis after angioplasty or in-stent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of salvianolic acid A in preparation of medicine for resisting tunica intima thickening, post-angioplasty restenosis and/or in-stent restenosis
  • Application of salvianolic acid A in preparation of medicine for resisting tunica intima thickening, post-angioplasty restenosis and/or in-stent restenosis
  • Application of salvianolic acid A in preparation of medicine for resisting tunica intima thickening, post-angioplasty restenosis and/or in-stent restenosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1. SAA inhibits the proliferation of human umbilical artery smooth muscle cells induced by PDGF-BB

[0038] Experimental Materials:

[0039] Human umbilical artery smooth muscle cells (hUASMCs) were purchased from ScienCell (Carlsbad, Calif). Smooth muscle cell culture medium: ScienCell (Carlsbad, Calif), fetal bovine serum FBS (Gibco). PDGF-BB was purchased from R&D Company. SAA was dissolved in DMSO into a 20mM stock solution, and the final concentration of DMSO was less than 0.1%, which had no effect on the growth of smooth muscle cells. The stock solution was aliquoted and stored in a -20°C refrigerator in the dark.

[0040] human umbilical artery smooth muscle cells 4 The density of each well was planted in a 96-well plate until 50% confluence, the serum was withdrawn and incubated for 48 hours, then according to the experimental design, 0, 0.1, 0.3 and 1 μM SAA were added for pre-incubation for 24 hours, and then 20ng / ml PDGF-BB were respectively conti...

Embodiment 2

[0044] Example 2. SAA inhibits the cell cycle of human umbilical artery smooth muscle cells

[0045] Cell culture method is the same as embodiment 1. smooth muscle cells at 5×10 6 The density was planted in a 100mm petri dish until it was 50% confluent, and cultured in serum-free DMEM medium for 48h. Give different concentrations of SAA for pre-incubation for 24 hours, then give 20ng / ml PDGF-BB stimulation, and continue to incubate for 48 hours; collect the cell supernatant, digest the cells with 0.25% trypsin, collect the cell suspension, centrifuge at 1000r / min×5min, discard supernatant. Fix with 70% cold ethanol pre-cooled at 4°C for 18h, then adjust the cell concentration to 10 6 / ml, stained with propidium iodide (PI) and incubated at 37°C for 30 min, followed by flow cytometry analysis, and the percentage of cells in each phase of the cell cycle was analyzed by using ModFitLT3.0 software; the cell proliferation index (PI) was calculated, PI = (S+G2 / M) / (G0 / G1+S+G2 / M)....

Embodiment 3

[0050] Example 3. Experimental study of SAA against restenosis after balloon-injured common carotid artery in rats

[0051] The restenosis model of rat common carotid artery balloon injury is an internationally recognized classic animal model of restenosis after PTA and in-stent restenosis.

[0052] Experimental materials: salvianolic acid A (purity ≥ 98%), made into 0.01mg / mL with triple distilled water; male SD rats with a body weight of 300-350g (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) .

[0053] Experimental method: the rats were randomly divided into 3 groups, namely the sham operation group, the model group and the salvianolic acid A group; after intraperitoneal anesthesia with 30% chloral hydrate 0.1mL / 100g. The skin and subcutaneous tissue were incised in the front of the neck, the common carotid artery and the internal carotid artery were clamped with arterial clips, a wedge-shaped incision was made in the external carotid arter...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of salvianolic acid A in preparation of medicine for resisting tunica intima thickening, post-angioplasty restenosis and / or in-stent restenosis. Experimental research finds that salvianolic acid A can restrain proliferation of umbilical cord artery blood vessel smooth muscle cells of a person and reduce the tunica intima thickening rate and the blood vessel lumen restenosis rate of a tunica intima thickening animal model after balloon injury, has the remarkable effects of resisting tunica intima thickening and post-angioplasty restenosis and / or in-stent restenosis, can be used for preparing the medicine for restraining tunica intima thickening, post-angioplasty restenosis and / or in-stent restenosis and is particularly used for preparing medicine for preventing post-percutaneous coronary angioplasty restenosis and in-stent restenosis or used for preparing a drug eluting stent. In this way, efficient, safe and economical prevention and treatment medicine and an efficient, safe and economical solution are provided for prevention and treatment of post-angioplasty, particularly post-percutaneous coronary angioplasty restenosis and in-stent restenosis.

Description

technical field [0001] The present invention relates to a new application of salvianolic acid A, a chemical component extracted from Salvia miltiorrhiza, in the preparation of medicines, and mainly relates to the preparation of salvianolic acid A in the preparation of anti-intima thickening and / or anti-restenosis after angioplasty and / or The application in stent restenosis drugs, particularly relates to the application of salvianolic acid A in the preparation of anti-restenosis after percutaneous transluminal coronary angioplasty and the application of in-stent restenosis drugs, which belongs to the technical field of medicine. Background technique [0002] The vascular wall is composed of vascular intima, media and adventitia, and is a physiological structure for the maintenance of important functions such as metabolism, nutrient supply, and blood pressure regulation of tissues and organs. The tunica intima is the innermost layer of the vessel wall, composed of endothelium ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61P9/10
Inventor 杜冠华孙岚赵睿张莉何国荣宋俊科秦至臻杨胜乾
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap